Parameters | Tenofovir-exposed patients (n=201) | Tenofovir-unexposed patients (n=123) | P value |
---|---|---|---|
Male, n (%) | 145 (72.1) | 92 (74.8) | 0.82 |
Black, n (%) | 11 (5.4) | 5 (4.1) | 0.71 |
IDU, n (%) | 28 (13.9) | 7 (5.7) | 0.03 |
H/BSX, n (%) | 108 (53.7) | 74 (60.1) | 0.58 |
Age, years1 | 42.5 (34.2-50.1) | 42.9 (33.6-51.4) | 0.48 |
Diabetes mellitus, n (%) | 12 (5.9) | 7 (5.7) | 0.91 |
Arterial hypertension, n (%) | 25 (12.4) | 14 (11.4) | 0.67 |
Malignancies, n (%) | 15 (7.5) | 9 (7.3) | 0.79 |
Chronic hepatitis B, n (%) | 19 (9.4) | 6 (4.9) | 0.006 |
Chronic hepatitis C, n (%) | 28 (13.9) | 13 (10.6) | 0.56 |
AIDS, n (%) | 29 (14.4) | 16 (13) | 0.66 |
CD4 lymphocyte count (cells/μL) 1 | 215 (88-301) | 207 (91-289) | 0.44 |
HIV RNA (log10/mL) 1 | 4.4 (3.9-5.1) | 4.6 (3.9-5.2) | 0.81 |
Creatinine (mg/dL) 1 | 0.87 (0.71-1.05) | 0.82 (0.73-1.02) | 0.72 |
GFR (mL/min/1.73m2)1 | 96.2 (83.2-111.4) | 93.1 (82.1-109.4) | 0.75 |
Current use of diuretics, n (%) | 17 (8.5) | 9 (7.3) | 0.71 |
Current use of ACE inhibitors, n (%) | 21 (10.4) | 11 (8.9) | 0.77 |
Current antiretroviral agents, n (%): - abacavir - zidovudine - stavudine - lamivudine - emtricitabine - lopinavir/ritonavir - atazanavir/ritonavir - fosamprenavir/ritonavir - nevirapine - efavirenz |
0 0 0 45 (22.4) 156 (77.6) 25 (12.4) 56 (27.9) 5 (2.5) 17 (8.4) 98 (48.7) |
78 (63.4) 25 (20.3) 2 (1.6) 119 (96.7) 4 (3.2) 11 (8.9) 34 (27.6) 1 (0.8) 11 (8.9) 66 (53.6) |
<0.001 <0.001 0.65 <0.001 <0.001 0.45 0.92 0.52 0.97 0.49 |